Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms
Completed · Phase 2
Conditions studied: Pancreatic Mucinous-Cystic Neoplasm
In brief
This study will evaluate intracystic NanoPac® (Sterile Nanoparticulate Paclitaxel) administered via endoscopic ultrasound-guided fine needle injection (EUS-FNI) in subjects with mucinous cystic pancreatic neoplasms.
Key facts
- Study ID
- NCT03188991
- Run by
- NanOlogy, LLC
- People needed
- 20
- Starts
- 2017-09-29
- Expected to finish
- 2020-06-29
- Last updated by the study team
- 2021-06-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Signed informed consent;
- Patients over the age of 18;
- Recently confirmed mucinous cystic pancreatic neoplasm; may be confirmed by presence of mucin, cyst fluid carcinoembryonic antigen (CEA) above 192 U/L, or other reliable diagnostic means such as endomicroscopy; KRAS analysis may also be performed at the discretion of the Investigator;
- Unilocular cyst with diameter of at least 1.5 cm but no more than 4 cm;
- Normal hematologic, hepatic, and renal function at study entry;
- Appropriate steps taken to minimize or avoid the potential for pregnancy for subjects of child-bearing potential.*
- Note: A female patient is considered to be of childbearing potential unless she has had a hysterectomy, is at least one year postmenopausal or has undergone tubal ligation. For the purposes of this study, adequate birth control includes at least one medically approved and highly effective method of birth control, defined as those which result in a low failure rate (i.e., < 1% per year) when used consistently and correctly, such as implants, injectables and oral contraceptives combined with the use of condoms. Only male patients whose vasectomy has been confirmed by semen analysis at least 3 months after the vasectomy are allowed not to use acceptable contraceptive methods.
You may not qualify if…
- Positive cytology indicating malignancy;
- Thrombotic or embolic events;
- Known hypersensitivity to study agent;
- Known drug or alcohol abuse;
- Pregnant or breastfeeding women.
Where it is running
- Parkview Cancer Institute — Fort Wayne, Indiana, United States
- The Ohio State University, Wexner Medical Center — Columbus, Ohio, United States
- Texas Tech University Health Sciences Center — El Paso, Texas, United States
- Baylor College of Medicine — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.